Please ensure Javascript is enabled for purposes of website accessibility

Why Cara Therapeutics Shares Jumped 10% Today

By Todd Campbell – May 25, 2018 at 2:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor optimism continues following an important licensing deal earlier in the week.

What happened

Cara Therapeutics' (CARA 3.92%) stock has been on a tear following news that Vifor Fresenius Medical Care Renal Pharma Ltd. licensed certain ex-U.S. rights to Korsuva, Cara Therapeutics' treatment for chronic kidney disease-associated itching in dialysis patients. Since the news was reported, Cara Therapeutics shares have risen from less than $12 per share to over $17 per share, including a gain of as much as 12.5% on Friday.

So what

Korsuva is a kappa opioid receptor agonist that relieves pain by targeting nerves in sensory nerves. Because it doesn't target the central nervous system like traditional opioids, it doesn't carry the same risks of abuse or of side effects that they do.

A man in a suit reaching his hand out to shake someone else's hand.


Last year, Cara Therapeutics reported that Korsuva reduced pain in kidney disease patients with chronic itch by 68% versus placebo on a 0-to-10 rating scale. The findings prompted Cara Therapeutics to initiate a pivotal phase 3 study that's currently ongoing and spurred Vifor Fresenius' interest in securing rights to the drug.

In exchange for rights to use Korsuva for chronic itch in dialysis patients located outside of the U.S., Japan, and South Korea, Cara Therapeutics is receiving $50 million in upfront cash, and it can receive up to $470 million in additional milestones, including $30 million in regulatory milestones and $440 million in sales milestones. Furthermore, it can receive tiered royalties on sales in licensed territories. 

Vifor Fresenius Medical Care Renal Pharma Ltd is also acquiring $20 million of Cara Therapeutics stock at a price of roughly $17 per share. 

Now what

Cara Therapeutics is retaining its full rights to Korsuva injection in this indication in the U.S., except in Fresenius Medical Care North America dialysis clinics. In those clinics, Cara Therapeutics will promote Korsuva and share profits with Vifor. 

Teaming up with Vifor is a big win for Cara Therapeutics because Fresenius is a Goliath in dialysis. There are roughly 468,000 Americans in kidney failure who receive dialysis, and Fresenius clinics treat about 38% of them. Fresenius' global presence in key markets means Cara Therapeutics is spared the expense of trying to come up with and pay for an international commercialization strategy -- and that's a win, too.

Having said that, phase 3 data isn't available yet to confirm Korsuva's efficacy. Therefore, there is a risk that Korsuva will fail to make it to the finish line. There's no set timeline yet for the data in dialysis patients, but the primary completion date listed in is February 2019. Before then, we will see data in June 2018 from a separate phase 3 trial evaluating the use of Korsuva in post-operative pain.

Overall, this is great news for the company given that investor optimism was crimped last summer when an oral formulation of Korsuva failed to deliver in hip and knee pain patients. Whether the company's share price continues to rally this year, however, could depend significantly on Korsuva's post-operative pain trial results later this quarter, so investors will want to pay close attention to this stock when that data is unveiled. 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
$9.01 (3.92%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.